个人中心 - 老虎社区

肥猫z

IP属地：广东

帖子 · 59帖子 · 59
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 肥猫z肥猫z
  ·06-11 15:06
  $阿里巴巴-W(09988)$ 为啥被压制的这么狠？
  220 评论
  1
  分享
  举报
- 肥猫z肥猫z
  ·06-11 15:05
  $小米集团-W(01810)$ 要是到22必做多了
  111 评论
  1
  分享
  举报
- 肥猫z肥猫z
  ·06-11 15:02
  $康方生物(09926)$ 和 $百济神州(06160)$ 和$荃信生物-B(02509)$ 低位齐企稳迹象，创新药板块回暖的话，资金必抢！
  129 评论
  2
  分享
  举报
- 肥猫z肥猫z
  ·06-04
  $京玖康疗(00648)$ 连阳节奏
  194 评论
  1
  分享
  举报
- 肥猫z肥猫z
  ·06-04
  $首钢朗泽(02553)$ 新股好猛
  154 评论
  1
  分享
  举报
- 肥猫z肥猫z
  ·06-04
  $XI二南策略-U(09399)$ 继续玩一把
  44 评论
  1
  分享
  举报
- 肥猫z肥猫z
  ·06-04
  $荃信生物-B(02509)$ 开始止跌，罗氏合作的基本面没变，15附近安全性高！
  238 评论
  1
  分享
  举报
- 肥猫z肥猫z
  ·05-28
  $泡泡玛特(09992)$ 今天能先上170吗？
  200 评论
  1
  分享
  举报
- 肥猫z肥猫z
  ·05-28
  $小米集团-W(01810)$ 大V天龙🐉
  120 评论
  1
  分享
  举报
- 肥猫z肥猫z
  ·05-28
  $荃信生物-B(02509)$ QX031N第一期在顺利推进，之前股价被压着，就是在等这样的硬催化！
  荃信生物-B(02509)就完成QX031N I期临床试验首例受试者给药收到罗氏支付的里程碑付款
  智通财经APP讯，荃信生物-B 公布，公司已于2026年5月27日收到合作伙伴F.Hoffmann-LaRoche Ltd支付的里程碑付款，该付款乃基于QX031N项目完成I期临床试验首例受试者给药而触发。该研究于2026年3月27日完成首例受试者给药。于2025年10月28日，公司与罗氏达成全球独家合作与许可协议，授予罗氏开发、生产及商业化QX031N的全球独家权益。
  荃信生物-B(02509)就完成QX031N I期临床试验首例受试者给药收到罗氏支付的里程碑付款
  272 评论
  1
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4223619148654702","uuid":"4223619148654702","gmtCreate":1760515947577,"gmtModify":1760518234227,"name":"肥猫z","pinyin":"fmzfeimaoz","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":59,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":574044726044808,"gmtCreate":1781161587048,"gmtModify":1781161632659,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/09988\">$阿里巴巴-W(09988)$&nbsp;</a> 为啥被压制的这么狠？","listText":"<a href=\"https://laohu8.com/S/09988\">$阿里巴巴-W(09988)$&nbsp;</a> 为啥被压制的这么狠？","text":"$阿里巴巴-W(09988)$ 为啥被压制的这么狠？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/574044726044808","isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":574044869580312,"gmtCreate":1781161556259,"gmtModify":1781161632516,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$&nbsp;</a> 要是到22必做多了","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$&nbsp;</a> 要是到22必做多了","text":"$小米集团-W(01810)$ 要是到22必做多了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/574044869580312","isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":574043636603144,"gmtCreate":1781161327862,"gmtModify":1781170243971,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/09926\">$康方生物(09926)$&nbsp;</a>&nbsp;和 <a href=\"https://laohu8.com/S/06160\">$百济神州(06160)$&nbsp;</a>&nbsp;和<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a>&nbsp; 低位齐企稳迹象，创新药板块回暖的话，资金必抢！","listText":"<a href=\"https://laohu8.com/S/09926\">$康方生物(09926)$&nbsp;</a>&nbsp;和 <a href=\"https://laohu8.com/S/06160\">$百济神州(06160)$&nbsp;</a>&nbsp;和<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a>&nbsp; 低位齐企稳迹象，创新药板块回暖的话，资金必抢！","text":"$康方生物(09926)$ 和 $百济神州(06160)$ 和$荃信生物-B(02509)$ 低位齐企稳迹象，创新药板块回暖的话，资金必抢！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/574043636603144","isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":571515925669952,"gmtCreate":1780554443536,"gmtModify":1780554571893,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/00648\">$京玖康疗(00648)$ </a> 连阳节奏","listText":"<a href=\"https://laohu8.com/S/00648\">$京玖康疗(00648)$ </a> 连阳节奏","text":"$京玖康疗(00648)$ 连阳节奏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/571515925669952","isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":571514746917232,"gmtCreate":1780554414431,"gmtModify":1780554571919,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02553\">$首钢朗泽(02553)$ </a> 新股好猛","listText":"<a href=\"https://laohu8.com/S/02553\">$首钢朗泽(02553)$ </a> 新股好猛","text":"$首钢朗泽(02553)$ 新股好猛","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/571514746917232","isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":571514659477976,"gmtCreate":1780554206280,"gmtModify":1780554553303,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/09399\">$XI二南策略-U(09399)$ </a> 继续玩一把","listText":"<a href=\"https://laohu8.com/S/09399\">$XI二南策略-U(09399)$ </a> 继续玩一把","text":"$XI二南策略-U(09399)$ 继续玩一把","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/571514659477976","isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":571513830285720,"gmtCreate":1780554024347,"gmtModify":1780554534307,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> 开始止跌，罗氏合作的基本面没变，15附近安全性高！","listText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> 开始止跌，罗氏合作的基本面没变，15附近安全性高！","text":"$荃信生物-B(02509)$ 开始止跌，罗氏合作的基本面没变，15附近安全性高！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/571513830285720","isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":569121679245960,"gmtCreate":1779949930431,"gmtModify":1779950620376,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/09992\">$泡泡玛特(09992)$&nbsp;</a> 今天能先上170吗？","listText":"<a href=\"https://laohu8.com/S/09992\">$泡泡玛特(09992)$&nbsp;</a> 今天能先上170吗？","text":"$泡泡玛特(09992)$ 今天能先上170吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/569121679245960","isVote":1,"tweetType":1,"viewCount":200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":569121603715216,"gmtCreate":1779949904769,"gmtModify":1779950620302,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$&nbsp;</a> 大V天龙🐉","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$&nbsp;</a> 大V天龙🐉","text":"$小米集团-W(01810)$ 大V天龙🐉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/569121603715216","isVote":1,"tweetType":1,"viewCount":120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":569121496477856,"gmtCreate":1779949878840,"gmtModify":1779950620227,"author":{"id":"4223619148654702","authorId":"4223619148654702","name":"肥猫z","avatar":"https://static.tigerbbs.com/7c49f64b5dc447e62550179cd19d7a81","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4223619148654702","authorIdStr":"4223619148654702"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> QX031N第一期在顺利推进，之前股价被压着，就是在等这样的硬催化！","listText":"<a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$ </a> QX031N第一期在顺利推进，之前股价被压着，就是在等这样的硬催化！","text":"$荃信生物-B(02509)$ QX031N第一期在顺利推进，之前股价被压着，就是在等这样的硬催化！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/569121496477856","repostId":"2638880146","repostType":2,"repost":{"id":"2638880146","kind":"news","pubTimestamp":1779886738,"share":"https://www.laohu8.com/m/news/2638880146?lang=zh_CN&edition=full","pubTime":"2026-05-27 20:58","market":"fut","language":"zh","title":"荃信生物-B(02509)就完成QX031N I期临床试验首例受试者给药收到罗氏支付的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2638880146","media":"智通财经","summary":"智通财经APP讯，荃信生物-B 公布，公司已于2026年5月27日收到合作伙伴F.Hoffmann-LaRoche Ltd支付的里程碑付款，该付款乃基于QX031N项目完成I期临床试验首例受试者给药而触发。该研究于2026年3月27日完成首例受试者给药。于2025年10月28日，公司与罗氏达成全球独家合作与许可协议，授予罗氏开发、生产及商业化QX031N的全球独家权益。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02509\">荃信生物-B</a>(02509)公布，公司已于2026年5月27日收到合作伙伴F.Hoffmann-LaRoche Ltd(以下简称“罗氏”)支付的里程碑付款，该付款乃基于QX031N(罗氏研发代码：RG6981)项目完成I期临床试验首例受试者给药而触发。</p><p>QX031N已于新西兰开展一项I期、首次人体试验、随机、研究者与受试者双盲、安慰剂对照、单剂量与多剂量递增、平行组研究，旨在评估QX031N在健康受试者、慢性阻塞性肺疾病(COPD)受试者及哮喘受试者中的安全性、耐受性、药代动力学和药效学。该研究于2026年3月27日完成首例受试者给药。</p><p>于2025年10月28日，公司与罗氏达成全球独家合作与许可协议，授予罗氏开发、生产及商业化QX031N的全球独家权益。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荃信生物-B(02509)就完成QX031N I期临床试验首例受试者给药收到罗氏支付的里程碑付款</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荃信生物-B(02509)就完成QX031N I期临床试验首例受试者给药收到罗氏支付的里程碑付款\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-27 20:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1446843.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，荃信生物-B(02509)公布，公司已于2026年5月27日收到合作伙伴F.Hoffmann-LaRoche Ltd(以下简称“罗氏”)支付的里程碑付款，该付款乃基于QX031N(罗氏研发代码：RG6981)项目完成I期临床试验首例受试者给药而触发。QX031N已于新西兰开展一项I期、首次人体试验、随机、研究者与受试者双盲、安慰剂对照、单剂量与多剂量递增、平行组研究，旨在评估...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1446843.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"source_url":"http://www.zhitongcaijing.com/content/detail/1446843.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2638880146","content_text":"智通财经APP讯，荃信生物-B(02509)公布，公司已于2026年5月27日收到合作伙伴F.Hoffmann-LaRoche Ltd(以下简称“罗氏”)支付的里程碑付款，该付款乃基于QX031N(罗氏研发代码：RG6981)项目完成I期临床试验首例受试者给药而触发。QX031N已于新西兰开展一项I期、首次人体试验、随机、研究者与受试者双盲、安慰剂对照、单剂量与多剂量递增、平行组研究，旨在评估QX031N在健康受试者、慢性阻塞性肺疾病(COPD)受试者及哮喘受试者中的安全性、耐受性、药代动力学和药效学。该研究于2026年3月27日完成首例受试者给药。于2025年10月28日，公司与罗氏达成全球独家合作与许可协议，授予罗氏开发、生产及商业化QX031N的全球独家权益。","news_type":1,"symbols_score_info":{"02509":1.5}},"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}